Effects of dipeptidyl peptidase-4 inhibitor treatment doses on tuberculosis in patients with diabetes: a long-term nationwide population-based cohort study

doi:10.21037/apm-20-278

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24535

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24535

Title:	Effects of dipeptidyl peptidase-4 inhibitor treatment doses on tuberculosis in patients with diabetes: a long-term nationwide population-based cohort study
Authors:	Chen, HH;Hsieh, MC;Ho, CW;Chen, CC;Hsu, SP;Lin, CL;Kao, CH
Keywords:	Dipeptidyl peptidase-4 inhibitor (DPP4i);tuberculosis (TB);diabetes
Date:	2020
Issue Date:	2022-08-09T08:03:57Z (UTC)
Publisher:	AME PUBL CO
ISSN:	2224-5820
Abstract:	Background: To investigate the association of dipeptidyl peptidase-4 inhibitors (DPP4is) treatment doses and tuberculosis (TB) in patients with diabetes. Methods: We allocated participants into DPP4i users and non-users from the Longitudinal Health Insurance Database. A chi-square test and Wilcoxon's rank-sum test were, used to analyze the baseline discrete variables and continuous variable, respectively,. The incidence rate was calculated in 1,000 person-years. The hazard ratios (HRs) were adjusted using a multivariate Cox regression model. The effect of DDP4i dosage on 11,1 was analyzed. The Kaplan-Meier method was used to assess the cumulative incidence curves with a log-rank test. Results: We identified 6,399 DPP4i users and 6,399 non-users. The incidence rate of TB in DPP4i users and non-users was 22.2 and 16.2 per 1,000 person-years, respectively. The HR of TB for DPP4i users relative to non users was 1.04 (P=0.89). Most of the analysis of factors such as the incidence rate, gender and diabetic comorbidities in our study were non significant. The risk of developing TB in patients with over 20 average defined daily doses (DDDs) per year was increased by 2.19 times (P=0.048). Conclusions: In our long-term nationwide population-based cohort study, higher closes of DPP4i (20 average DDDs) could increase TB infection risk in patients with diabetes. To pay more attention to this kind of diabetic patients with DPP4i treatment will be more important for the public health issue of TB prevention.
URI:	http://dx.doi.org/10.21037/apm-20-278 https://www.webofscience.com/wos/woscc/full-record/WOS:000576670500046 https://ir.csmu.edu.tw:8080/handle/310902500/24535
Relation:	ANNALS OF PALLIATIVE MEDICINE ,2020 ,v9 ,issue 5 ,p2817-2825
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	180	View/Open

Loading...